Tempus AI is trading at $79.59, down 4.74%, with no clear company-specific catalyst confirmed for the October 6 decline.

  • FDA clearance for its ECG-MR product was reported earlier and coincided with the prior session’s 9.03% gain, so it does not explain today’s drop.
  • The broader market is higher, with the S&P 500 up 0.72%, Nasdaq Composite up 0.67%, and Dow up 0.69%; this direction does not explain Tempus AI’s decline.